Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 75/100

Failure Rate

16.7%

1 terminated/withdrawn out of 6 trials

Success Rate

66.7%

-19.8% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 2 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 1
5(83.3%)
Phase 2
1(16.7%)
6Total
Phase 1(5)
Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials
NCT00683761Phase 1Unknown

A Study of 131I-TM601 in Adults With Recurrent Malignant Glioma

Role: lead

NCT00591058Phase 1Unknown

Safety and Dose-Finding Study of TM-601 in Adults With Recurrent Malignant Glioma

Role: lead

NCT00733798Phase 1Terminated

A Safety and Efficacy Study of Intravenous 131I-TM601 in Adult Patients With Malignant Melanoma

Role: lead

NCT00114309Phase 2Unknown

131-I-TM-601 Study in Adults With Recurrent High-Grade Glioma

Role: lead

NCT00379132Phase 1Completed

131-I-TM-601 Study in Adults With Solid Tumors

Role: lead

NCT00040573Phase 1Completed

Safety and Tolerability Study of 131I-TM-601 to Treat Adult Patients With Recurrent Glioma.

Role: lead

All 6 trials loaded